Won-Suk Lee
Head of Business Development ADEL
Seminars
Thursday 10th December 2026
ADEL-Y03 (Anti-MHC-I-unbound β2-microglobulin Antibody) for Treatment of Neurodegenerative Diseases & Beyond
3:00 pm
- Pathological Mechanism: β2m accumulation disrupts the neuro-immune axis and co-aggregates with Aβ, accelerating neurotoxic pathways and cognitive decline independently of amyloid plaques
- Selective Strategy: ADEL-Y03 utilizes an epitope-focused design to specifically neutralize “free” β2m while sparing MHC-I, ensuring high safety and selectivity
- Therapeutic Efficacy: Preclinical data confirms ADEL-Y03 rescues cognitive deficits in AD models and shows potential broader indications, including systemic fibrosis
